SofWave Medical (SOFW) Q2 2024 earnings summary

Executive summary

• Q2 revenue was $14.642M, up 18% YoY; H1 revenue was $27.826M, up 22% YoY.

• Q2 recurring revenue reached $6.0M, up 83% YoY; more than 325,000 treatments had been delivered to date.

• Operating losses narrowed substantially, and 2024 operating break-even was reaffirmed; June 30 cash was $21.081M.

Financial highlights

• Q2 revenue was $14.642M vs. $12.380M in Q2 2023; H1 revenue was $27.826M vs. $22.787M.

• Q2 gross profit was $11.148M vs. $9.239M; H1 gross profit was $21.062M vs. $16.910M.

• Q2 operating loss was $1.213M vs. $2.876M; H1 operating loss was $2.170M vs. $6.616M.

• H1 net loss was $2.513M vs. $6.668M; basic and diluted loss per share was $0.07 vs. $0.20.

Outlook and guidance

• 2024 operating break-even was reaffirmed, excluding stock-based compensation; revenue growth, gross-margin improvement, expense discipline and a historically stronger Q4 were cited.

• Lean, scalable infrastructure and investment in sales coverage and practice development are intended to support growth and profitability.

• Existing funding and forecast cash flows are expected to support operations for the foreseeable future; new-product commercialization depends on development and regulatory approvals.